This study tested whether never-hospitalized adults with specialist-confirmed long COVID (LC) — breathless (BLC, n=80) or non-breathless (NBLC, n=37) — had evidence of hypercoagulability, impaired fibrinolysis, abnormal fibrin architecture, or increased fibrin(ogen) microaggregates compared to fully recovered COVID-19 controls (n=34), using a broad panel of hemostasis biomarkers and quantitative confocal fibrin analysis.
No significant differences were found between LC groups and controls across all prothrombotic markers (D-dimer, fibrinogen, VWF, thrombomodulin, P-selectin, PAI-1, 50% clot lysis time, NETosis markers), fibrin fiber density (47.9 vs. 43.6 vs. 38.0 fibers/100 µm; P=0.22), or fibrin(ogen) microaggregate number and area; no meaningful correlations were found with breathlessness, fatigue, or pulmonary perfusion/gas transfer metrics.
Single time-point sampling; subgroup-only fibrin microaggregate analysis (n=55); population was largely White/Caucasian; findings are not generalizable to hospitalized LC patients, who represent a different severity spectrum.
Antithrombotic therapy (e.g., anticoagulants, plasma exchange) is not supported for never-hospitalized long COVID in the absence of a separate recognized thrombotic indication. Clinicians should not prescribe these treatments outside clinical trials based on the 'microclot' hypothesis.